Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

Ipatasertib, an AKT inhibitor, in combination with prednisone and abiraterone, is under evaluation for the treatment of metastatic castration‐resistant prostate cancer (mCRPC). Hyperglycemia is an on‐target effect of ipatasertib. An open‐label, single‐arm, single‐sequence, signal‐seeking study (n = ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutaria, Dhruvitkumar S., Agarwal, Priya, Huang, Kuan‐Chieh, Miles, Dale R., Rotmensch, Jacob, Hinton, Heather, Gallo, Jorge Daniel, Rasuo, Grozdana, Sane, Rucha S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747122/
https://www.ncbi.nlm.nih.gov/pubmed/36197694
http://dx.doi.org/10.1111/cts.13420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747122/
https://www.ncbi.nlm.nih.gov/pubmed/36197694
http://dx.doi.org/10.1111/cts.13420

Ejemplares similares